Veracyte Q3 Revenues Increase 75 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Veracyte said after the close of the market on Monday that revenues in its third quarter improved 75 percent year over year.

The South San Francisco, Calif.-based company, which went public earlier this month, raising $58 million in net proceeds, reported revenues of $5.6 million for the three months ended Sept. 30, up from $3.2 million in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.